Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics to Receive $1.1M for Sequencing 50 Tumor-Normal Pairs in NCI Pediatric Cancer Study

Premium

Complete Genomics said this week that it will be paid $1.1 million, or $11,000 per genome, to sequence and analyze 50 pediatric tumor-normal pairs for a National Cancer Institute-led study that is funded by the American Recovery and Reinvestment Act of 2009.

The company previously disclosed the order in its registration statement for an initial public offering filed last month with the US Securities and Exchange Commission. According to the filing, Complete received the order in May from SAIC-Frederick, the main contractor for the NCI's R&D facility in Frederick, Md., and will sequence the 100 genomes over a six-month period. SAIC then has the option to have the company analyze the genomes of more than 500 additional tumor-normal pairs over an 18-month period (IS 8/3/2010).

This week, Complete Genomics said that the project is part of an NCI initiative called Therapeutically Applicable Research to Generate Effective Treatments, which seeks to use genomic technologies to rapidly identify therapeutic targets in childhood cancers. The TARGET project currently focuses on acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma, and Wilms tumor.

Complete Genomics will seek to identify and validate mutations in the tumor genomes, including SNPs, insertions and deletions, and copy number variations. It expects to submit the sequence data as well as the assembled and validated data sets to the National Center for Biotechnology Information's Sequence Read Archive database and the TARGET database.

Last month, the company said that as of mid-July, it had sequenced 200 humans this year, and had an order backlog of more than 500 genomes.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.